U.S. markets closed

Fagron NV (EBR:FAGR) Earns A Nice Return On Capital Employed

Simply Wall St

Today we are going to look at Fagron NV (EBR:FAGR) to see whether it might be an attractive investment prospect. To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business.

First up, we'll look at what ROCE is and how we calculate it. Second, we'll look at its ROCE compared to similar companies. And finally, we'll look at how its current liabilities are impacting its ROCE.

Understanding Return On Capital Employed (ROCE)

ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. All else being equal, a better business will have a higher ROCE. Ultimately, it is a useful but imperfect metric. Renowned investment researcher Michael Mauboussin has suggested that a high ROCE can indicate that 'one dollar invested in the company generates value of more than one dollar'.

So, How Do We Calculate ROCE?

The formula for calculating the return on capital employed is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

Or for Fagron:

0.14 = €84m ÷ (€801m - €192m) (Based on the trailing twelve months to December 2019.)

Therefore, Fagron has an ROCE of 14%.

See our latest analysis for Fagron

Does Fagron Have A Good ROCE?

When making comparisons between similar businesses, investors may find ROCE useful. Fagron's ROCE appears to be substantially greater than the 7.9% average in the Healthcare industry. I think that's good to see, since it implies the company is better than other companies at making the most of its capital. Regardless of where Fagron sits next to its industry, its ROCE in absolute terms appears satisfactory, and this company could be worth a closer look.

You can see in the image below how Fagron's ROCE compares to its industry. Click to see more on past growth.

ENXTBR:FAGR Past Revenue and Net Income, March 14th 2020

Remember that this metric is backwards looking - it shows what has happened in the past, and does not accurately predict the future. ROCE can be misleading for companies in cyclical industries, with returns looking impressive during the boom times, but very weak during the busts. ROCE is, after all, simply a snap shot of a single year. What happens in the future is pretty important for investors, so we have prepared a free report on analyst forecasts for Fagron.

How Fagron's Current Liabilities Impact Its ROCE

Current liabilities are short term bills and invoices that need to be paid in 12 months or less. Due to the way the ROCE equation works, having large bills due in the near term can make it look as though a company has less capital employed, and thus a higher ROCE than usual. To counteract this, we check if a company has high current liabilities, relative to its total assets.

Fagron has current liabilities of €192m and total assets of €801m. As a result, its current liabilities are equal to approximately 24% of its total assets. A fairly low level of current liabilities is not influencing the ROCE too much.

Our Take On Fagron's ROCE

With that in mind, Fagron's ROCE appears pretty good. There might be better investments than Fagron out there, but you will have to work hard to find them . These promising businesses with rapidly growing earnings might be right up your alley.

I will like Fagron better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.